(LEGN) – PRNewswire
-
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
-
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
-
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
-
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
-
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
-
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
-
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
-
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations
-
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
-
Riding the Waves of Foreign Trade: The Rise of China's Brands in 2023
-
ICHNOS SCIENCES WELCOMES LIDA PACAUD, M.D., AS NEW CHIEF MEDICAL OFFICER
-
CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held
-
Genscript Biotech Reports 2022 Annual Results*
-
Jackie Veivia-Panter Joins BioCentriq as Chief Quality and Compliance Officer
-
The International Myeloma Foundation (IMF) Highlights #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2022
-
GenScript to Host 2nd Annual Gene & Cell Engineering Virtual Summit
-
PM360 Announces Winners of The Eighth Annual ELITE Awards
-
Genscript Biotech Reports 2021 Annual Results
-
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
-
China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again
-
Cellares Appoints John Tomtishen as Vice President of Operations
-
GenScript Biotech Reports First Half 2021 Results
-
GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
-
Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multipl
-
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple
-
GenScript Reports 2020 Interim Results and Provides Business Update
Back to LEGN Stock Lookup